Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03, Zacks reports. The business had revenue of $10.74 million during the quarter, compared to the consensus estimate of $2.21 million. Arbutus Biopharma had a negative return on equity of 57.48% and a negative net margin of 352.24%.
Arbutus Biopharma Price Performance
ABUS stock remained flat at $3.40 during mid-day trading on Friday. The company's stock had a trading volume of 637,103 shares, compared to its average volume of 874,529. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.01 and a quick ratio of 6.01. The stock's 50 day moving average is $3.32 and its 200 day moving average is $3.31. The company has a market capitalization of $651.20 million, a P/E ratio of -11.72 and a beta of 0.86. Arbutus Biopharma has a 12-month low of $2.70 and a 12-month high of $4.72.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Arbutus Biopharma stock. Goldman Sachs Group Inc. raised its stake in Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) by 290.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,075,948 shares of the biopharmaceutical company's stock after purchasing an additional 1,544,070 shares during the quarter. Goldman Sachs Group Inc. owned approximately 1.08% of Arbutus Biopharma worth $7,245,000 at the end of the most recent reporting period. 43.79% of the stock is owned by institutional investors.
About Arbutus Biopharma
(
Get Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
